share_log

MusclePharm (OTCMKTS:MSLP) Stock Price Crosses Below 200-Day Moving Average of $0.20

Defense World ·  Oct 19, 2022 02:31

MusclePharm Co. (OTCMKTS:MSLP – Get Rating) shares crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.20 and traded as low as $0.11. MusclePharm shares last traded at $0.23, with a volume of 10,774 shares traded.

MusclePharm Price Performance

The firm has a market capitalization of $7.65 million, a price-to-earnings ratio of -0.39 and a beta of 0.38. The firm has a 50 day moving average price of $0.17 and a 200-day moving average price of $0.20.

About MusclePharm

(Get Rating)

MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products.

Recommended Stories

  • Get a free copy of the StockNews.com research report on MusclePharm (MSLP)
  • Does J&J Have Enough Alpha to Be a Solid Low Beta Stock?
  • This Mid Cap Energy Stock is a 10-Bagger...And May Not Be Done
  • Should You Make a Reservation in Marriott International Stock?
  • The Outperforming Software Stock No One is Talking About
  • Will Goldman Sachs' Earnings & Revenue Beats Lift Sector Higher?

Receive News & Ratings for MusclePharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MusclePharm and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment